In 903 adults in Pakistan primed with Sinovac, AZD1222 or natural infection, ½ and ⅓ dose BNT162b2 boosters were non-inferior to full-dose Sinovac (day-28 seroresponse 66.7% and 70.5% vs 19.4%) but not to full-dose BNT162b2 in any priming group. No serious adverse events.
RCTn = 903
Hussain et al. Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan